Asia Proteomics Leader, Bertis, Participates in ' Asia Summit on Global Health 2024'

-    Invited as the only Korean company to participate in the event hosted by the Hong Kong Special Administrative Region on May 16-17... Dr. Sangtae Kim, Chief Scientist of Informatics and AI, will attend as a speaker.

-    Sharing insights on proteomics technologies and applications that Asia should focus on, including early cancer detection blood tests, during the session on ‘Advancing Healthcare in Asia Through Innovation’ on May 17

[Image] Asia Summit on Global Health, Bertis Logo

On May 16th, Bertis, a company specializing in the development of proteomics-based precision medicine technology (led by CEOs Dong-young Noh and Seung-man Han), announced that it will participate in the '4th Asia Summit on Global Health 2024 (ASGH 2024)', which will be held at the Hong Kong Convention and Exhibition Center (HKCEC) on May 16th and 17th.

ASGH, jointly organized by the Government of the Hong Kong Special Administrative Region and the Hong Kong Trade Development Council (HKTDC), aims to promote innovative medical technology development and support investment activation to seek a more sustainable future amid global issues such as aging population, novel infectious diseases, and climate-related health threats.

At ASGH 2024, key officials from the governments of China and the Hong Kong Special Administrative Region, as well as executives from global leading pharmaceutical and biotech companies and research institutions, buyers, and investors active in the Asian region, will participate. Themed ‘Innovation, Inclusion, Impact’, ASGH 2024 will compromise a series of thematic sessions focusing on the latest trends in different medical sectors. Project pitching and deal-making meetings will also be organized to facilitate business discussions and investment partnerships. Bertis, as a leader in Asia's proteomics, is invited as the only Korean company to participate. Dr. Sangtae Kim, Chief Scientist of Informatics and AI at Bertis, will speak, introducing proteomics technologies that Asia's medical industry should focus on for development, and will share insights into their applications and importance.

Dr. Kim will participate in the session titled 'Advancing Healthcare in Asia Through Innovation' on May 17th. He will highlight how proteomics technology is rapidly advancing and providing opportunities for precise disease diagnosis, personalized treatment tailored to individuals, and drug target discovery. Particularly, he will introduce proteomics-based early cancer detection blood tests as an innovative technology that will bring significant changes to the healthcare industry in Asia. He plans to emphasize the importance of investing in and leading the development of proteomics technology and industry in the Asian region.

Dr. Kim stated, "I am honored to have the opportunity to discuss the future direction of Asian healthcare with global leaders in Hong Kong, the hub of Asia. Proteomics technology is essential for realizing precision medicine and plays a crucial role in addressing key challenges faced by the healthcare sector in Asia. I will do my utmost to promote regional collaboration and highlight the importance of this technology in overcoming these challenges."

Bertis combines more than a decade of accumulated expertise in proteomics with bioinformatics to identify biomarkers for various major diseases, including cancer. These biomarkers are then utilized in the development of diagnostic and analytical solutions. In 2019, Bertis introduced MASTOCHECK®, the world's first proteomics-based early breast cancer detection blood test. The company is currently working on developing early detection blood tests for pancreatic cancer and ovarian cancer as part of its ongoing pipeline. Additionally, Bertis is engaged in the research and development of SAN (Spectrum is All you Need) model, aiming to create an innovative health information interpretation model that can extract health insights from proteomic biological data using AI technology.